High serum APRIL levels also strongly correlate with severity in pediatric atopic eczema (AE), both during flare and quiescence, implicating APRIL as a reliable marker of AE severity in children and highlighting APRIL as a promising target for treatment of AE (103). The gene discussed is TNFSF13; the disease is atopic eczema.